Patient characteristics
| Rozrolimupab dose groups . | ||||||||
|---|---|---|---|---|---|---|---|---|
| Characteristic . | 75 μg/kg . | 100 μg/kg . | 125 μg/kg . | 150 μg/kg . | 200 μg/kg . | 250 μg/kg . | 300 μg/kg . | All . |
| N | 11 | 10 | 10 | 5 | 6 | 6 | 13 | 61 |
| Sex | ||||||||
| Female | 3 (27.3%) | 9 (90.0%) | 6 (60.0%) | 4 (80.0%) | 5 (83.3%) | 5 (83.3%) | 7 (53.8%) | 39 (63.9%) |
| Male | 8 (72.7%) | 1 (10.0%) | 4 (40.0%) | 1 (20.0%) | 1 (16.7%) | 1 (16.7%) | 6 (46.2%) | 22 (36.1%) |
| Age, y | ||||||||
| Median | 51.0 | 40.0 | 41.0 | 52.0 | 60.5 | 42.5 | 55.0 | 51.0 |
| Range | 40.0-65.0 | 19.0-75.0 | 26.0-74.0 | 32.0-62.0 | 25.0-81.0 | 21.0-74.0 | 25.0-77.0 | 19.0-81.0 |
| Age category | ||||||||
| < 40 y | 0 | 4 (40.0%) | 5 (50.0%) | 2 (40.0%) | 2 (33.3%) | 3 (50.0%) | 4 (30.8%) | 20 (32.8%) |
| 40-60 y | 10 (90.9%) | 4 (40.0%) | 3 (30.0%) | 2 (40.0%) | 1 (16.7%) | 1 (16.7%) | 7 (53.8%) | 28 (45.9%) |
| > 60 y | 1 (9.1%) | 2 (20.0%) | 2 (20.0%) | 1 (20.0%) | 3 (50.0%) | 2 (33.3%) | 2 (15.4%) | 13 (21.3%) |
| Race | ||||||||
| Asian | 0 | 0 | 0 | 0 | 0 | 1 (16.7%) | 5 (38.5%) | 6 (9.8%) |
| White | 11 (100%) | 10 (100%) | 9 (90.0%) | 5 (100%) | 6 (100%) | 5 (83.3%) | 8 (61.5%) | 54 (88.5%) |
| Other | 0 | 0 | 1 (10.0%) | 0 | 0 | 0 | 0 | 1 (1.6%) |
| Body mass index, kg/m2 | ||||||||
| Median | 26.0 | 23.6 | 25.9 | 28.9 | 27.2 | 27.3 | 26.7 | 26.1 |
| Range | 18.5-36.8 | 18.0-30.8 | 21.0-38.1 | 22.7-30.5 | 18.7-31.3 | 20.1-38.7 | 21.1-40.7 | 18.0-40.7 |
| Time from first ITP diagnosis to screening, mo | ||||||||
| Median | 68 | 20 | 5 | 8 | 27 | 28 | 19 | 21 |
| Range | 1-166 | 4-354 | 2-187 | 4-141 | 1-117 | 3-223 | 1-273 | 1-354 |
| Baseline platelet count, × 109/L | ||||||||
| Median | 11.5 | 22.3 | 13.3 | 20.5 | 19.3 | 16.0 | 18.5 | 18.5 |
| Range | 5.0-24.5 | 10.5-26.5 | 3.0-26.5 | 4.5-21.5 | 3.0-26.0 | 6.0-26.0 | 7.3-27.0 | 3.0-27.0 |
| Rozrolimupab dose groups . | ||||||||
|---|---|---|---|---|---|---|---|---|
| Characteristic . | 75 μg/kg . | 100 μg/kg . | 125 μg/kg . | 150 μg/kg . | 200 μg/kg . | 250 μg/kg . | 300 μg/kg . | All . |
| N | 11 | 10 | 10 | 5 | 6 | 6 | 13 | 61 |
| Sex | ||||||||
| Female | 3 (27.3%) | 9 (90.0%) | 6 (60.0%) | 4 (80.0%) | 5 (83.3%) | 5 (83.3%) | 7 (53.8%) | 39 (63.9%) |
| Male | 8 (72.7%) | 1 (10.0%) | 4 (40.0%) | 1 (20.0%) | 1 (16.7%) | 1 (16.7%) | 6 (46.2%) | 22 (36.1%) |
| Age, y | ||||||||
| Median | 51.0 | 40.0 | 41.0 | 52.0 | 60.5 | 42.5 | 55.0 | 51.0 |
| Range | 40.0-65.0 | 19.0-75.0 | 26.0-74.0 | 32.0-62.0 | 25.0-81.0 | 21.0-74.0 | 25.0-77.0 | 19.0-81.0 |
| Age category | ||||||||
| < 40 y | 0 | 4 (40.0%) | 5 (50.0%) | 2 (40.0%) | 2 (33.3%) | 3 (50.0%) | 4 (30.8%) | 20 (32.8%) |
| 40-60 y | 10 (90.9%) | 4 (40.0%) | 3 (30.0%) | 2 (40.0%) | 1 (16.7%) | 1 (16.7%) | 7 (53.8%) | 28 (45.9%) |
| > 60 y | 1 (9.1%) | 2 (20.0%) | 2 (20.0%) | 1 (20.0%) | 3 (50.0%) | 2 (33.3%) | 2 (15.4%) | 13 (21.3%) |
| Race | ||||||||
| Asian | 0 | 0 | 0 | 0 | 0 | 1 (16.7%) | 5 (38.5%) | 6 (9.8%) |
| White | 11 (100%) | 10 (100%) | 9 (90.0%) | 5 (100%) | 6 (100%) | 5 (83.3%) | 8 (61.5%) | 54 (88.5%) |
| Other | 0 | 0 | 1 (10.0%) | 0 | 0 | 0 | 0 | 1 (1.6%) |
| Body mass index, kg/m2 | ||||||||
| Median | 26.0 | 23.6 | 25.9 | 28.9 | 27.2 | 27.3 | 26.7 | 26.1 |
| Range | 18.5-36.8 | 18.0-30.8 | 21.0-38.1 | 22.7-30.5 | 18.7-31.3 | 20.1-38.7 | 21.1-40.7 | 18.0-40.7 |
| Time from first ITP diagnosis to screening, mo | ||||||||
| Median | 68 | 20 | 5 | 8 | 27 | 28 | 19 | 21 |
| Range | 1-166 | 4-354 | 2-187 | 4-141 | 1-117 | 3-223 | 1-273 | 1-354 |
| Baseline platelet count, × 109/L | ||||||||
| Median | 11.5 | 22.3 | 13.3 | 20.5 | 19.3 | 16.0 | 18.5 | 18.5 |
| Range | 5.0-24.5 | 10.5-26.5 | 3.0-26.5 | 4.5-21.5 | 3.0-26.0 | 6.0-26.0 | 7.3-27.0 | 3.0-27.0 |